Vivos Therapeutics Profit Margin

The latest profit margin for VVOS is -122.08% as of June 2026. That compares with -99.49% in the prior-year period — down 22.7% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Vivos Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VVOS's profit margin moved from -99.49% to -122.08% — a 22.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vivos Therapeutics's valuation or profitability profile.

Against Healthcare companies, VVOS currently prints -122.08% for profit margin, while the sector average sits near 13.76%. That is roughly 987.2% below the sector mean. Large gaps often invite a closer look at Vivos Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Vivos Therapeutics converts resources into returns. At -122.08%, VVOS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -99.49% in the prior-year period — down 22.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VVOS's profit margin (-122.08%), review year-over-year change from -99.49%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.